Don't fall victim to this 'diagnosis' that was invented just to sell drugs

This ‘pre-disease’ may be the worst of all

I’ve told you about the contagious epidemic of “pre-disease syndrome.” These are “diseases” like pre-menopause, pre-dementia and pre-diabetes.

Some aren’t even real conditions. And others can be reversed with minor changes or may need no treatment at all.

But one of worst of these ‘preevies’ has to be osteopenia. It’s the pre-disease to osteoporosis.

And like the others in this syndrome, a diagnosis of osteopenia can mean your doctor pulls out his Rx pad.

But osteopenia is nothing more than a normal condition that has been ingeniously marketed as a risky “disease.”

The whole concept of a pre-osteoporosis was invented by some hot and tired researchers at a meeting in Rome 22 years ago. Even the name — osteopenia — came from an off-the-cuff comment.

But Merck saw a big opportunity, and ran with it to sell its “new” drug Fosamax. And they did such a great job that a whole lot of other drugs to “treat” osteopenia have come down the pike since.

And the real story behind this made-up disease — well, that’s one that Big Pharma would rather you never, ever hear.

In 1992, World Health Organization researchers in Rome dreamed up the word osteopenia (literally: bone poverty) to define diminished bone density. Just about everyone experiences bone density loss as a natural part of aging. So you may have perfectly healthy bones, but just not quite as dense at 45 as they were at 35. That’s osteopenia.

Here’s how Merck turned osteopenia into a billion-dollar baby in four easy steps…

STEP ONE: Change the system to fit the drug.

In 1995, the FDA approved Fosamax — Merck’s osteoporosis drug. But this “breakthrough” drug wasn’t a blockbuster at first because there was a little diagnostic problem.

At the time, the only method to measure bone density in the spine and hips (the critical osteoporosis points) required cumbersome and expensive equipment. Screening was difficult and costly to the patient, so women weren’t getting screened in large numbers.

Another technique used “peripheral machines” to measure bone density in a finger or a wrist. These machines were smaller and less expensive — an obvious plus. But measurements of peripheral bones don’t reveal what’s going on in the spine and hips. Bone loss in one part of the skeleton isn’t necessarily the same in another part.

That critical detail didn’t bother Merck officials. They launched a campaign to widely promote the use of peripheral machines which could be easily and much less expensively used in doctors’ offices. This gave a boost to the number of people screened, a huge boost to the number of diagnosed osteoporosis cases, and an equally huge boost to Fosamax sales.

STEP TWO: Get some help from friends in Congress.

Want to REALLY improve your business? Throw a ton of money at Congress.

Intensive lobbying efforts by Merck paid off in 1997 with the Bone Mass Measurement Act. Under this act, bone scans were covered by Medicare. So Merck got another triple boost: more screenings, more osteoporosis cases, more Fosamax sales.

STEP THREE: Get some help from friends at the FDA.

1997 was a big year for Merck. In addition to purchasing the Medicare boost from Congress, they developed a low-dose Fosamax pill and got the FDA to approve this “new” pill as a treatment for a condition that requires no treatment at all: osteopenia.

Doctors played right along and now Fosamax and other osteoporosis drugs are regularly prescribed for osteopenia.

STEP FOUR: Get more help from those FDA buddies.

Four years ago, FDA officials announced that they could find no evidence that bisphosphonate drugs, such as Fosamax, Boniva, Reclast, etc., increase risk of femur fractures just below the hip joint. That same month, two studies showed that long-term use of this class of drugs absolutely does appear to increase fracture risk.

Is this a disaster in the making for Merck? Not quite. After a brilliant marketing run of well over a decade, Merck’s luck held out beyond the date when the patent for Fosamax expired in 2008.

Merck wins. Patients lose.

Except those, like us, who realize that marketing campaigns aren’t medicine.

Tell your friends to just say “no” to drug therapy for osteopenia.

“How a Bone Disease Grew To Fit the Prescription” Alix Spiegel, NPR, 12/21/09,